BACKGROUND Studies have shown that patients with chronic renal failure(CRF)are more likely to suffer from breast cancer and other malignant tumors.To our knowledge,CRF can reduce drug excretion,thereby increase drug e...BACKGROUND Studies have shown that patients with chronic renal failure(CRF)are more likely to suffer from breast cancer and other malignant tumors.To our knowledge,CRF can reduce drug excretion,thereby increase drug exposure and lead to increased toxicity,which will limit drug treatment and lead to tumor progression.Currently,there are few successful reports on the combination of docetaxel,trastuzumab,and pertuzumab(THP)as a neoadjuvant treatment regimen for breast cancer patients with CRF.CASE SUMMARY We report a breast cancer(cT2N2M0,Her-2+/HR-)patient with CRF.It was a clinical stage IIIA tumor on the left breast.The patient had suffered from uremia for 2 years,and her heart function was normal.Based on the pathological type,molecular type,and clinical stage of breast cancer,and the patient’s renal function,the clinician analyzed the pharmacological and pharmacokinetic characteristics of the antitumor drugs after consulting the relevant literature,and prescribed the neoadjuvant regimen of THP(docetaxel 80 mg/m²,trastuzumab 8 mg/kg for the first dose,and 6 mg/kg for the maintenance dose with pertuzumab 840 mg for the first dose and 420 mg for the maintenance dose),once every 3 wk,for a total of 6 courses.The neoadjuvant treatment had a good effect,and the patient then underwent surgery which was uneventful.CONCLUSION CRF is not a contraindication for systemic treatment and surgery of breast cancer.The THP regimen without dose adjustment may be a safe and effective neoadjuvant treatment for HER-2 positive breast cancer patients with CRF.展开更多
Objective:This study aimed to explore the relationship between cohesin subunit REC8 reduction and meiosis chromosome segregation errors in the ovary.Methods:Rec8^(+/-)mice were generated using CRIPSR/Cas9 gene editing...Objective:This study aimed to explore the relationship between cohesin subunit REC8 reduction and meiosis chromosome segregation errors in the ovary.Methods:Rec8^(+/-)mice were generated using CRIPSR/Cas9 gene editing.The association between age and REC8 expression levels in the ovary was determined by Western blotting.Chromosome segregation errors were investigated by immunofluorescence imaging of superovulated oocytes.Wild-type andRec8^(+/-)female mice at 5,8,20,36,and 40 weeks were used to evaluate ovarian reserve by ovarian clearing and immunolabeling.Results:Ovary REC8 expression levels gradually decreased with age,while chromosome segregation errors increased with age.Segregation errors were more common inRec8^(+/-)mice,suggesting an association with REC8 expression.The ovarian reserve capacity decreased significantly with age.The ovarian reserve inRec8^(+/-)mice was inferior to that of age-matched wild-type mice,indicating important roles of age and REC8 levels in the ovarian reserve.Conclusions:REC8 reduction has an age-cumulative effect on meiotic chromosome segregation errors in mouse ovaries.Rec8 haploinsufficiency poses a major challenge in generating normal and reproductive oocytes in aging mice.展开更多
文摘BACKGROUND Studies have shown that patients with chronic renal failure(CRF)are more likely to suffer from breast cancer and other malignant tumors.To our knowledge,CRF can reduce drug excretion,thereby increase drug exposure and lead to increased toxicity,which will limit drug treatment and lead to tumor progression.Currently,there are few successful reports on the combination of docetaxel,trastuzumab,and pertuzumab(THP)as a neoadjuvant treatment regimen for breast cancer patients with CRF.CASE SUMMARY We report a breast cancer(cT2N2M0,Her-2+/HR-)patient with CRF.It was a clinical stage IIIA tumor on the left breast.The patient had suffered from uremia for 2 years,and her heart function was normal.Based on the pathological type,molecular type,and clinical stage of breast cancer,and the patient’s renal function,the clinician analyzed the pharmacological and pharmacokinetic characteristics of the antitumor drugs after consulting the relevant literature,and prescribed the neoadjuvant regimen of THP(docetaxel 80 mg/m²,trastuzumab 8 mg/kg for the first dose,and 6 mg/kg for the maintenance dose with pertuzumab 840 mg for the first dose and 420 mg for the maintenance dose),once every 3 wk,for a total of 6 courses.The neoadjuvant treatment had a good effect,and the patient then underwent surgery which was uneventful.CONCLUSION CRF is not a contraindication for systemic treatment and surgery of breast cancer.The THP regimen without dose adjustment may be a safe and effective neoadjuvant treatment for HER-2 positive breast cancer patients with CRF.
基金Shanghai Municipal Science and Technology Major Project(2017 SHZDZX01)。
文摘Objective:This study aimed to explore the relationship between cohesin subunit REC8 reduction and meiosis chromosome segregation errors in the ovary.Methods:Rec8^(+/-)mice were generated using CRIPSR/Cas9 gene editing.The association between age and REC8 expression levels in the ovary was determined by Western blotting.Chromosome segregation errors were investigated by immunofluorescence imaging of superovulated oocytes.Wild-type andRec8^(+/-)female mice at 5,8,20,36,and 40 weeks were used to evaluate ovarian reserve by ovarian clearing and immunolabeling.Results:Ovary REC8 expression levels gradually decreased with age,while chromosome segregation errors increased with age.Segregation errors were more common inRec8^(+/-)mice,suggesting an association with REC8 expression.The ovarian reserve capacity decreased significantly with age.The ovarian reserve inRec8^(+/-)mice was inferior to that of age-matched wild-type mice,indicating important roles of age and REC8 levels in the ovarian reserve.Conclusions:REC8 reduction has an age-cumulative effect on meiotic chromosome segregation errors in mouse ovaries.Rec8 haploinsufficiency poses a major challenge in generating normal and reproductive oocytes in aging mice.
